Table of Contents
Chemotherapy Research and Practice
Volume 2014 (2014), Article ID 174039, 5 pages
http://dx.doi.org/10.1155/2014/174039
Research Article

Electron Microscopy in Rat Brain Slices Reveals Rapid Accumulation of Cisplatin on Ribosomes and Other Cellular Components Only in Glia

1Department of Neuroscience, Universidad Central del Caribe, Bayamón, PR 00960, USA
2Department of Physiology, Universidad Central del Caribe, Bayamón, PR 00960, USA
3Department of Biochemistry, Universidad Central del Caribe, Bayamón, PR 00960, USA

Received 23 September 2014; Accepted 16 December 2014; Published 28 December 2014

Academic Editor: H. J. Schmoll

Copyright © 2014 Lidia Zueva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Y. Seiwert, J. K. Salama, and E. E. Vokes, “The chemoradiation paradigm in head and neck cancer,” Nature Clinical Practice Oncology, vol. 4, no. 3, pp. 156–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. B. F. Pan, D. H. Sweet, J. B. Pritchard, R. Chen, and J. A. Nelson, “A transfected cell model for the renal toxin transporter, rOCT2,” Toxicological Sciences, vol. 47, no. 2, pp. 181–186, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Yonezawa, “Platinum agent-induced nephrotoxicity via organic cation transport System,” Yakugaku Zasshi, vol. 132, no. 11, pp. 1281–1285, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Hayer-Zillgen, M. Brüss, and H. Bönisch, “Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3,” British Journal of Pharmacology, vol. 136, no. 6, pp. 829–836, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Y. Kucheryavykh, K. Rolón-Reyes, Y. V. Kucheryavykh et al., “Glioblastoma development in mouse brain: general reduction of OCTs and mislocalization of OCT3 transporter and subsequent uptake of ASP+ substrate to the nuclei,” Journal of Neuroscience and Neuroengineering, vol. 3, no. 1, pp. 3–9, 2014. View at Publisher · View at Google Scholar
  6. L. Y. Kucheryavykh, Y. V. Kucheryavykh, K. Rolón-Reyes et al., “Visualization of implanted GL261 glioma cells in living mouse brain slices using fluorescent 4-(4-(dimethylamino)-styryl)-N-methylpyridinium iodide (ASP+),” BioTechniques, vol. 53, no. 5, pp. 305–309, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. U. Karbach, J. Kricke, F. Meyer-Wentrup et al., “Localization of organic cation transporters OCT1 and OCT2 in rat kidney,” The American Journal of Physiology—Renal Physiology, vol. 279, no. 4, pp. F679–F687, 2000. View at Google Scholar · View at Scopus
  8. M. Inazu, H. Takeda, and T. Matsumiya, “Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes,” Journal of Neurochemistry, vol. 84, no. 1, pp. 43–52, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Y. Inyushin, A. Huertas, Y. V. Kucheryavykh et al., “L-DOPA uptake in astrocytic endfeet enwrapping blood vessels in rat brain,” Parkinson's Disease, vol. 2012, Article ID 321406, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. R. McWhinney, R. M. Goldberg, and H. L. McLeod, “Platinum neurotoxicity pharmacogenetics,” Molecular Cancer Therapeutics, vol. 8, no. 1, pp. 10–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Amptoulach and N. Tsavaris, “Neurotoxicity caused by the treatment with platinum analogues,” Chemotherapy Research and Practice, vol. 2011, Article ID 843019, 5 pages, 2011. View at Publisher · View at Google Scholar
  12. R. I. Roelofs, W. Hrushesky, J. Rogin, and L. Rosenberg, “Peripheral sensory neuropathy and cisplatin chemotherapy,” Neurology, vol. 34, no. 7, pp. 934–938, 1984. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Authier, J.-P. Gillet, J. Fialip, A. Eschalier, and F. Coudore, “An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections,” Experimental Neurology, vol. 182, no. 1, pp. 12–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. C. H. Pippitt Jr., H. B. Muss, H. D. Homesley, and V. W. Jobson, “Cisplatin-associated cortical blindness,” Gynecologic Oncology, vol. 12, no. 2, pp. 253–255, 1981. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. Gorman, R. Kefford, and R. Stuart-Harris, “Focal encephalopathy after cisplatin therapy,” Medical Journal of Australia, vol. 150, no. 7, pp. 399–401, 1989. View at Google Scholar · View at Scopus
  16. T. Boulikas and M. Vougiouka, “Cisplatin and platinum drugs at the molecular level,” Oncology Reports, vol. 10, no. 6, pp. 1663–1682, 2003. View at Google Scholar · View at Scopus
  17. E. M. Hlavin, M. B. Smeaton, and P. S. Miller, “Initiation of DNA interstrand cross-link repair in mammalian cells,” Environmental and Molecular Mutagenesis, vol. 51, no. 6, pp. 604–624, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. A. Hostetter, M. F. Osborn, and V. J. Derose, “RNA-Pt adducts following cisplatin treatment of saccharomyces cerevisiae,” ACS Chemical Biology, vol. 7, no. 1, pp. 218–225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Yu, J. Megyesi, and P. M. Price, “Cytoplasmic initiation of cisplatin cytotoxicity,” The American Journal of Physiology—Renal Physiology, vol. 295, no. 1, pp. F44–F52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Xu, C. Wang, and Z. Li, “A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress,” Molecular and Clinical Oncology, vol. 2, no. 1, pp. 3–7, 2013. View at Publisher · View at Google Scholar
  21. G. L. Beretta, S. C. Righetti, L. Lombardi, F. Zunino, and P. Perego, “Electron microscopy analysis of early localization of cisplatin in ovarian carcinoma cells,” Ultrastructural Pathology, vol. 26, no. 5, pp. 331–334, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Dore-Duffy and K. Cleary, “Morphology and properties of pericytes,” Methods in Molecular Biology, vol. 686, pp. 49–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. K. K. Filipski, R. H. Mathijssen, T. S. Mikkelsen, A. H. Schinkel, and A. Sparreboom, “Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity,” Clinical Pharmacology & Therapeutics, vol. 86, no. 4, pp. 396–402, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. M. Franke, A. M. Kosloske, C. S. Lancaster et al., “Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-β-D-glucosaminidase,” Clinical Cancer Research, vol. 16, no. 16, pp. 4198–4206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Ciarimboli, “Membrane transporters as mediators of cisplatin side-effects,” Anticancer Research, vol. 34, no. 1, pp. 547–550, 2014. View at Google Scholar · View at Scopus
  26. M. Sala-Rabanal, D. C. Li, G. R. Dake et al., “Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3,” Molecular Pharmaceutics, vol. 10, no. 4, pp. 1450–1458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Inyushin, Y. Kucheryavykh, L. Kucheryavykh et al., “Membrane potential and pH-dependent accumulation of decynium-22 (1,1-diethyl-2,2-cyanine iodide) fluorescence through OCT transporters in astrocytes,” Boletín de la Asociación Médica de Puerto Rico, vol. 102, no. 3, pp. 5–12, 2010. View at Google Scholar
  28. K. A. Heminger, S. D. Hartson, J. Rogers, and R. L. Matts, “Cisplatin inhibits protein synthesis in rabbit reticulocyte lysate by causing an arrest in elongation,” Archives of Biochemistry and Biophysics, vol. 344, no. 1, pp. 200–207, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. J. H. Cate, M. M. Yusupov, G. Z. Yusupova, T. N. Earnest, and H. F. Noller, “X-ray crystal structures of 70S ribosome functional complexes,” Science, vol. 285, no. 5436, pp. 2095–2104, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Meijera, M. J. A. van Luyn, E. F. Nienhuis, N. Blom, N. H. Mulder, and E. G. E. de Vries, “Ultrastructural morphology and localisation of cisplatin-induced platinum-DNA adducts in a cisplatin-sensitive and -resistant human small cell lung cancer cell line using electron microscopy,” Biochemical Pharmacology, vol. 61, no. 5, pp. 573–578, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. K. Zsengellér, L. Ellezian, D. Brown et al., “Cisplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity,” Journal of Histochemistry and Cytochemistry, vol. 60, no. 7, pp. 521–529, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Gilardini, R. L. Avila, N. Oggioni et al., “Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy,” NeuroToxicology, vol. 33, no. 1, pp. 1–7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. X.-B. Li and H. J. Schluesener, “Therapeutic effects of cisplatin on rat experimental autoimmune encephalomyelitis,” Archivum Immunologiae et Therapiae Experimentalis, vol. 54, no. 1, pp. 51–53, 2006. View at Publisher · View at Google Scholar · View at Scopus